NASD · Healthcare · Medical Devices · USA
ElectroCore Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
ElectroCore develops handheld bioelectronic devices that deliver nerve stimulation therapy. Its prescription products gammaCore and Quell Fibromyalgia treat headaches and chronic pain respectively, while Truvaga and TAC-STIM are consumer wellness devices. The company generates revenue primarily from government healthcare systems, particularly the United States Department of Veterans Affairs and the United Kingdom National Health Service.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the ElectroCore Inc stock.
Undervalued: intrinsic value $6.79 per share, market price $4.79, margin of safety 29.4% (as of 2026-11-17).
A 1.6x revenue multiple, discounted for its losses, values the shares at $6.79; the price of $4.79 is 29% below that value.
All 140 Medical Devices stocks
4 more in this industry show a wider margin of safety.
ECOR is undervalued (as of the 2026-11-17 close). A 1.6x revenue multiple, discounted for its losses, values the shares at $6.79; the price of $4.79 is 29% below that value.
$6.79 per share (as of the 2026-11-17 close), against a market price of $4.79. That is a margin of safety of 29.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.